Tomaymycin
Tomaymycin is an antitumor antibiotic. Tomaymycin has antimicrobial activity against Grampositive bacteria.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 35050-55-6
- Formule: C16H20N2O4
- Masse moléculaire:304.34
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
Description
IC50 & Target
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 35050-55-6
-
Masse moléculaire 304.34
-
Formule C16H20N2O4
-
SMILES
O=C1N2[C@](C/C(C2)=C\C)([H])[C@H](NC3=CC(O)=C(OC)C=C31)OC
-
Structure Classification
-
Initial Source
Streptomyces achromogenes
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
[1]. F L Boyd, et al. Characterization of a unique tomaymycin-d(CICGAATTCICG)2 adduct containing two drug molecules per duplex by NMR, fluorescence, and molecular modeling studies. Biochemistry. 1990 Mar 6;29(9):2387-403. [Content Brief]
[2]. K Arima, et al. Studies on tomaymycin, a new antibiotic. I. Isolation and properties of tomaymycin. J Antibiot (Tokyo). 1972 Aug;25(8):437-44. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tomaymycin Related Classifications
HY-N10174 Related Classifications
Powered by Bioz